Salesforce (CRM) Declined Following the Guidance

Core Insights - Columbia Threadneedle Investments reported a 12.06% return for its Columbia Global Technology Growth Fund in Q3 2025, slightly below the S&P Global 1200 Information Technology Index's return of 12.82% [1] - The fund's performance was positively influenced by stock selection, particularly in the context of strong earnings growth and enthusiasm for artificial intelligence [1] Company Performance - Salesforce, Inc. (NYSE:CRM) experienced a one-month return of 5.95% but saw a decline of 12.62% over the past 52 weeks, closing at $260.41 per share with a market capitalization of $247.91 billion on October 31, 2025 [2] - Salesforce's shares lagged in Q3 2025 due to conservative forward-looking guidance, which contrasted with high expectations for generative AI adoption [3] Innovation and Market Position - Salesforce launched its full-stack AI system, Agentforce, which has seen strong demand across various industries, along with a specialized AI platform for healthcare and pharmaceuticals [3] - In Q2 2026, Salesforce reported revenue of $10.25 billion, marking a 10% year-over-year increase and 9% growth in constant currency [4]